PLB-001

N/A

Report date: 2025/07/09 16:21:41

Base Information

Drug NamePLB-001
Drug Alias NamePLB-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA topoisomerase I inhibitorsAnti-Delta-like protein 3
TargetsDNA topoisomerase IDelta-like protein 3
Therapy Area/IndicationsLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesPrimeLink BioTherapeutics
China Registration ClassN/A

Develop Information

Active CompaniesPrimeLink BioTherapeutics
Inactive CompaniesN/A
Active IndicationsLung Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A